Publications
98
Citations
2,165
Est. group size
~6
Recurring co-author estimate
Active years
18
Publishing since 2008
Ye Zhou's work focuses on clinical and translational cancer research, especially gastrointestinal stromal tumors (GIST), gastric and gastroesophageal cancers, and kidney (renal cell) cancer, with an emphasis on testing new drug therapies and predicting patient outcomes. The research spans clinical trials of targeted therapies and immunotherapy combinations, biomarker studies, and development of prognostic models to guide treatment decisions.
Publication output has grown substantially over the past decade, rising from a handful of papers per year before 2021 to a peak of 26 in 2023, with continued strong activity in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis
Gastroenterology · 2025
- Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research
Signal Transduction and Targeted Therapy · 2025
- Developing a patient-based utility value set for the EORTC QLU-C10D using the OPUF method in Chinese cancer patients
Quality of Life Research · 2025
- Conversion effects of PD-1 inhibitor camrelizumab (Cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial.
Journal of Clinical Oncology · 2025
- [Expression of Concern] Combination of the FGFR4 inhibitor PD173074 and 5‑fluorouracil reduces proliferation and promotes apoptosis in gastric cancer
Oncology Reports · 2025
- Oxycodone versus Sufentanil for Postoperative Recovery in Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Randomized Controlled Trial
Drug Design Development and Therapy · 2025
- Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Cancer · 2025
- Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience
PLoS ONE · 2024
- Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.
Journal of Clinical Oncology · 2024
- Combination targeted therapy of avapritinib and sunitinib for patients with refractory advanced gastrointestinal stromal tumors after failure of standard treatments: Early results from a multi-institutional pilot study.
Journal of Clinical Oncology · 2024
- Development and validation of a prognostic model predicting the prognosis of surgically treated non-clear cell renal cell carcinoma patients with tumor thrombus
Research Square · 2024
- Interferon‐responsive neutrophils and macrophages extricate SARS‐CoV‐2 Omicron critical patients from the nasty fate of sepsis
Journal of Medical Virology · 2024
- Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma
Cells · 2023
- Causal effects of hypertension on risk of erectile dysfunction: A two-sample Mendelian randomization study
Frontiers in Cardiovascular Medicine · 2023
- Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
European Journal of Cancer · 2023
- Journal of Clinical Oncology×12
- Research Square×6
- PubMed×4
- Clinical Cancer Research×2
- Oncology Reports×2
- Ashima Goyal
Medicine · The Ohio State University
- Manisha H. Shah
Medicine · The Ohio State University
- Bhavana Konda
Medicine · The Ohio State University
- Vineeth Sukrithan
Medicine · The Ohio State University
- Dramane Konate
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile